semaglutide cardiovascular outcomes 2025 news currently not cost-effective for heart patients without diabetes, study finds Cardiovascular Outcomes Associated with Semaglutide

It is not for human or animal consumption, not for therapeutic, diagnostic, veterinary, food, cosmetic, or any non-research applications

Phentermine should not be taken indefinitely

Cagrilintide vs tirzepatide Tirzepatide is a dual GIP/GLP-1 agonist that produces the highest monotherapy weight loss results currently available, approximately 22.5% at the maximum dose

[So many people are] scared of vaccines and pharmaceuticals, but then were like, Oh, I want this peptide, even though it says Not for human use on the bottle. Are there new business opportunities for BPC-157

NC Medicaid removed obesity coverage October 2025

The 10 mg vial contains high-purity lyophilized powder for laboratory research